{"id":"W2101199621","doi":"10.1002/hep.26386","title":"Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial","year":2013,"lang":"en","type":"article","venue":"Hepatology","topic":"Hepatitis C virus research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada); University of Alberta","funders":"Gilead Sciences; Pfizer; Bristol-Myers Squibb","keywords":"Ribavirin; Medicine; Gastroenterology; Internal medicine; Adverse effect; Hepatitis C virus; Viral load; Boceprevir; Immunology; Human immunodeficiency virus (HIV); Virus","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001244344,0.00121819,0.001418486,0.0002232286,0.0003276443,0.0008347883,0.0007495572,0.0009668302,0.005215868],"category_scores_gemma":[0.0006671377,0.0003706496,0.001106331,0.0002324476,0.0006365664,0.0006227199,0.0002925126,0.002123882,0.0008379088],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005759348,"about_ca_system_score_gemma":0.0009325027,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007426728,"about_ca_topic_score_gemma":0.00226286,"domain_scores_codex":[0.9996351,0.00020246,0.00002128796,0.00004931591,0.00002586048,0.00006593738],"domain_scores_gemma":[0.9995753,0.00007332917,0.00007183888,0.00002840607,0.00002575218,0.0002253965],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9319474,0.007682756,0.003409049,0.000691982,0.0009073874,0.0001223093,0.00008216573,0.0006809995,0.004312337,0.0001831405,0.001726049,0.04825455],"study_design_scores_gemma":[0.8749768,0.1139096,0.00699183,0.00007909475,0.0004430653,0.0001595121,0.00003626215,0.0007598971,0.0009237339,0.0001230711,0.001578983,0.00001811885],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9911748,0.004358842,0.0001437651,0.000664974,0.0001792432,0.0008243805,0.0005285752,0.00006974702,0.00205574],"genre_scores_gemma":[0.9936026,0.001642896,0.0003872549,0.0006754781,0.0002360513,0.0006508285,0.0007574219,0.0000086364,0.002038848],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005215868,"threshold_uncertainty_score":0.01744878,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01512678579575553,"score_gpt":0.2764275641954025,"score_spread":0.261300778399647,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}